Proteintech

PD-L1/CD274 Monoclonal Antibody (2B11D11)

Product Image Gallery

PD-L1/CD274 Antibody in Immunocytochemistry (ICC/IF) — Immunofluorescent analysis of ( 10% Formaldehyde ) fixed HeLa cells using 66248-1-IG (PD-L1/CD274 antibody) at dilution of 1:300 and Alexa Fluor 488-conjugated AffiniPure Goat Anti-Mouse IGG (H+L).

PD-L1/CD274 Antibody in Immunohistochemistry (Paraffin) (IHC (P)) — Immunohistochemistry of paraffin-embedded human lung cancer tissue slide using 66248-1-Ig (PD-L1/CD274 Antibody) at dilution of 1:1000 (under 10x lens). heat mediated antigen retrieved with Sodium Citrate buffer (pH 6).

PD-L1/CD274 Antibody in Western Blot (WB) — Untreated and PNGase F-treated lysates of THP-1 cells and HepG2 cells were subjected to SDS PAGE followed by western blot with 66248-1-Ig (PD-L1/CD274 antibody) at dilution of 1:5000 incubated at room temperature for 1.5 hours. PNGase F was obtained from Atagenix (cat.NO. ata808).

PD-L1/CD274 Antibody in Flow Cytometry (Flow) — 1X10^6 Raji cells were stained with 0.2ug PD-L1/CD274 antibody (66248-1-IG, red) and control antibody (blue). Fixed with 4% PFA blocked with 3% BSA (30 min). Alexa Fluor 488-conjugated AffiniPure Goat Anti-Mouse IGG (H+L) with dilution 1:1500.

Product Details

66248-1-IG

Applications	Tested Dilution	Publications
Western Blot (WB)	1:2,000-1:10,000	View 5 publications 5 publications
Immunohistochemistry (IHC)	-	View 9 publications 9 publications
Immunohistochemistry (Paraffin) (IHC (P))	1:500-1:2,000	-
Immunocytochemistry (ICC/IF)	1:50-1:500	View 1 publication 1 publication
Flow Cytometry (Flow)	0.2 µg/1x10^6 cells	-

Product Specifications
Species Reactivity	Human, Mouse, Pig, Rat
Published species	Human, Mouse
Host/Isotype	Mouse / IgG1
Class	Monoclonal
Type	Antibody
Clone	2B11D11
Immunogen	PD-L1/CD274 Fusion Protein Ag12443 (25-241 aa encoded by BC074984) View antigen
Conjugate	Unconjugated
Form	Liquid
Concentration	1.55 mg/mL
Purification	Protein G
Storage buffer	PBS, pH 7.3, with 50% glycerol
Contains	0.02% sodium azide
Storage conditions	-20°C

Product Specific Information

Immunogen sequence: KDLYVVEYG SNMTIECKFP VEKQLDLAAL IVYWEMEDKN IIQFVHGEED LKVQHSSYRQ RARLLKDQLS LGNAALQITD VKLQDAGVYR CMISYGGADY KRITVKVNAP YNKINQRILV VDPVTSEHEL TCQAEGYPKA EVIWTSSDHQ VLSGKTTTTN SKREEKLFNV TSTLRINTTT NEIFYCTFRR LDPEENHTAE LVIPELPLAH PPNERTHL (25-241 aa encoded by BC074984 )

Target Information

Programmed death receptor ligand 1 (PD-L1, also called B7-H1) is a recently described B7 family member. To date, one specific receptor has been identified that can be ligated by PD-L1. This receptor, programmed death receptor 1 (PD-1), has been shown to negatively regulate T-cell receptor (TCR) signaling. Upon ligating its receptor, PD-L1 has been reported to decrease TCR-mediated proliferation and cytokine production. PD-L1 expression was found to be abundant on many murine and human cancers and could be further up-regulated upon IFN-gamma stimulation. Thus, PD-L1 might play an important role in tumor immune evasion.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

Product References

CDK5 Regulates PD-L1 Expression and Cell Maturation in Dendritic Cells of CRSwNP.

Inflammation

Liu CC,Zhang HL,Zhi LL,Jin P,Zhao L,Li T,Zhou XM,Sun DS,Cheng GH,Xin Q,Shi L,Xia M

Fri Feb 01 00:00:00 EST 2019

CDK5 Regulates PD-L1 Expression and Cell Maturation in Dendritic Cells of CRSwNP.

Inflammation

Liu CC,Zhang HL,Zhi LL,Jin P,Zhao L,Li T,Zhou XM,Sun DS,Cheng GH,Xin Q,Shi L,Xia M

Fri Feb 01 00:00:00 EST 2019

MLL3 enhances the transcription of PD-L1 and regulates anti-tumor immunity.

Biochimica et biophysica acta. Molecular basis of disease

Xiong W,Deng H,Huang C,Zen C,Jian C,Ye K,Zhong Z,Zhao X,Zhu L

Fri Feb 01 00:00:00 EST 2019

MLL3 enhances the transcription of PD-L1 and regulates anti-tumor immunity.

Biochimica et biophysica acta. Molecular basis of disease

Xiong W,Deng H,Huang C,Zen C,Jian C,Ye K,Zhong Z,Zhao X,Zhu L

Fri Feb 01 00:00:00 EST 2019

PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery

Amoils M,Kim J,Lee C,Sunwoo JB,Colevas AD,Aasi SZ,Hollmig ST,Ma Y,Divi V

Tue Jan 01 00:00:00 EST 2019

Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy.

Respiratory research

Jin J,Si J,Liu Y,Wang H,Ni R,Wang J

Fri Oct 05 00:00:00 EDT 2018

Tristetraprolin Overexpression in Gastric Cancer Cells Suppresses PD-L1 Expression and Inhibits Tumor Progression by Enhancing Antitumor Immunity.

Molecules and cells

Guo J,Qu H,Shan T,Chen Y,Chen Y,Xia J

Tue Jul 31 00:00:00 EDT 2018

STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion.

Nature communications

Hsu JM,Xia W,Hsu YH,Chan LC,Yu WH,Cha JH,Chen CT,Liao HW,Kuo CW,Khoo KH,Hsu JL,Li CW,Lim SO,Chang SS,Chen YC,Ren GX,Hung MC

Tue May 15 00:00:00 EDT 2018

Association of PD-L1 and HIF-1α Coexpression with Poor Prognosis in Hepatocellular Carcinoma.

Translational oncology

Dai X,Pi G,Yang SL,Chen GG,Liu LP,Dong HH

Sun Apr 01 00:00:00 EDT 2018

A case of metastatic basal cell carcinoma treated with continuous PD-1 inhibitor exposure even after subsequent initiation of radiotherapy and surgery.

JAAD case reports

Cannon JGD,Russell JS,Kim J,Chang ALS

Sun Apr 01 00:00:00 EDT 2018

MiR-142 inhibits cecal ligation and puncture (CLP)-induced inflammation via inhibiting PD-L1 expression in macrophages and improves survival in septic mice.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Zhen J,Chen W

Mon Jan 01 00:00:00 EST 2018

Positive Expression of Programmed Death Ligand 1 in Peritumoral Liver Tissue is Associated with Poor Survival after Curative Resection of Hepatocellular Carcinoma.

Translational oncology

Dai X,Xue J,Hu J,Yang SL,Chen GG,Lai PBS,Yu C,Zeng C,Fang X,Pan X,Zhang T

Tue Aug 01 00:00:00 EDT 2017

Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells.

Clinical and experimental immunology

Jiao Q,Liu C,Li W,Li W,Fang F,Qian Q,Zhang X

Thu Jun 01 00:00:00 EDT 2017

Association Between Programmed Death Ligand 1 Expression in Patients With Basal Cell Carcinomas and the Number of Treatment Modalities.

JAMA dermatology

Chang J,Zhu GA,Cheung C,Li S,Kim J,Chang AL

Sat Apr 01 00:00:00 EDT 2017

Efficacy of short-term nivolumab treatment in a Chinese patient with relapsed advanced-stage lung squamous cell carcinoma: A case report.

Medicine

Pi G,He H,Bi J,Li Y,Li Y,Zhang Y,Wang M,Han G,Lin C

Sat Oct 01 00:00:00 EDT 2016

Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma.

Journal of translational medicine

Song Z,Yu X,Cheng G,Zhang Y

Fri Jun 24 00:00:00 EDT 2016

Bioinformatics

Protein Aliases: B7 homolog 1; B7-H1; CD274; CD274 antigen; PD-L1; PDCD1 ligand 1; pdl-1; Programmed cell death 1 ligand 1; programmed death ligand 1; sCD274; soluble CD274; soluble PD L1; sPD L1

Gene Aliases: A530045L16Rik; B7-H; B7H1; CD274; PD-L1; PDCD1L1; PDCD1LG1; PDL1; RGD1566211

UniProt ID: (Human) Q9NZQ7, (Mouse) Q9EP73

Entrez Gene ID: (Pig) 574058, (Human) 29126, (Mouse) 60533, (Rat) 499342

Molecular Function: immunoglobulin receptor superfamily